-transparent.png){kind=logo}
Thirty-three patients with advanced breast cancer were treated with a recombinant alpha interferon (rIFN-alpha 2). All patients were ambulatory (performance status greater than or equal to 50 Karnofsky scale) and almost all had received previous chemotherapy. Large intravenous dosages of 30 to 50 X 10(6) IU/m2 were given for five consecutive days every two to three weeks to 22 patients and smaller subcutaneous dosage of 2 X 10(6) IU/m2 three times a week to 11 patients. No complete or partial responses were seen. Two patients had stable disease and the remainder progressed. Flu-like syndromes were seen in all patients. Nausea, vomiting, and anorexia were frequent. Hypotension and confusion were noted in six and five patients, respectively. Life-threatening leukopenia was noted in two patients receiving intravenous dosage and thrombocytopenia was noted in one; no sepsis or bleeding complications were noted. In this study, a highly purified and biologically active rIFN-alpha 2 was not associated with activity in previously treated women with metastatic breast cancer.
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
November 1994,
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
October 1995,
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
September 1990,
Molecular biotherapy,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
July 2001,
European journal of cancer (Oxford, England : 1990),
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
November 1989,
British journal of urology,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
May 1992,
British journal of urology,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
July 1991,
Urology,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
July 1986,
Cancer,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
January 1998,
Journal of neuro-oncology,
H B Muss, and
R A Kempf, and
S Martino, and
S A Rudnick, and
J Greiner, and
M R Cooper, and
D Decker, and
S M Grunberg, and
D V Jackson, and
F Richards
June 1994,
American journal of clinical oncology,
